Macrolide therapy decreases chronic obstructive pulmonary disease exacerbation: A meta-analysis

Respiration

Volumn 86, Issue 3, 2013, Pages 254-260

  Yao, Guo Yan ^a,b   Ma, Yan Liang ^a   Zhang, Mo Qin ^a   Gao, Zhan Cheng ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b Huaishuling Branch of Beijing Fengtai Hospital of Integrated Traditional Chinese and Western Medicine   (China)

Author keywords

Chronic obstructive pulmonary disease; Exacerbation; Macrolide; Meta analysis

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; RIBOFLAVIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; PLACEBO; THEOPHYLLINE;

ANTIBIOTIC THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG EFFECT; DRUG SAFETY; FOLLOW UP; HUMAN; LONG TERM CARE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; EMBASE; MEDLINE; OUTCOME ASSESSMENT; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

HUMANS; MACROLIDES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84885028632     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000350828     Document Type: Review

References (22)

1. Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management and prevention of COPD. 2011. http://www.goldcopd. org/.
2. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
3. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456.
4. Barnes PJ: Inhaled corticosteroids in COPD: a controversy. Respiration 2010; 80: 89-95.
5. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, et al: Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect 2011; 17:E1-E59.
6. Lopez-Boado YS, Rubin BK: Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr Opin Pharmacol 2008; 8: 286-291.
7. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG: Immunomodulatory effects of macrolide antibiotics. 1. Biological mechanisms. Respiration 2011; 81: 67-74.
8. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG: Immunomodulatory effects of macrolide antibiotics. 2. Advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration 2011; 81: 75-87.
9. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M: Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998; 157: 1829-1832.
10. Florescu DF, Murphy PJ, Kalil AC: Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis. Pulm Pharmacol Ther 2009; 22: 467-472.
11. Figueiredo Bde C, Ibiapina Cda C: The role of macrolides in noncystic fibrosis bronchiectasis. Pulm Med 2011; 2011: 751982.
12. Mammen MJ, Sethi S: Macrolide therapy for the prevention of acute exacerbations in chronic obstructive pulmonary disease. Pol Arch Med Wewn 2012; 122: 54-59.
13. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
14. Suzuki T, Yanai M, Yamaya M, Satoh-Nakagawa T, Sekizawa K, Ishida S, Sasaki H: Erythromycin and common cold in COPD. Chest 2001; 120: 730-733.
15. Banerjee D, Khair OA, Honeybourne D: The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respir Med 2005; 99: 208-215.
16. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA: Longterm erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178: 1139-1147.
17. Blasi F, Bonardi D, Aliberti S, Tarsia P, Confalonieri M, Amir O, Carone M, Di Marco F, Centanni S, Guffanti E: Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm Pharmacol Ther 2010; 23: 200-207.
18. He ZY, Ou LM, Zhang JQ, Bai J, Liu GN, Li MH, Deng JM, MacNee W, Zhong XN: Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration 2010; 80: 445-452.
19. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, et al: Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 689-698.
20. Poletti V, Casoni G, Chilosi M, Zompatori M: Diffuse panbronchiolitis. Eur Respir J 2006; 28: 862-871.
21. Periti P, Mazzei T, Mini E, Novelli A: Adverse effects of macrolide antibacterials. Drug Saf 1993; 9: 346-364.
22. Swanson DJ, Sung RJ, Fine MJ, Orloff JJ, Chu SY, Yu VL: Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med 1992; 92: 61-68.